Bayer's Retinal Pioneers Programme
Access resources developed in collaboration with thought leaders in ophthalmology
Established in 2018, Retinal Pioneers is a promotional programme organised and funded by Bayer, designed to contribute towards the evolution of retinal knowledge and catalyse innovation in medical retina. As part of the programme, this Retinal Pioneers Hub provides a source of on-demand, educational resources developed in collaboration with national and international thought leaders in ophthalmology. Materials on this hub are available throughout the year, with new content released quarterly.
Retinal Pioneers Summit (RPS)
The Retinal Pioneers Summit is an annual meeting designed to enable UK ophthalmologists to explore the latest innovations and scientific and clinical advancements in the management of medical retina conditions.
Read key takeaway messages from RPS 2024, including sessions such as:
- Introduction to aflibercept 8 mg: Key data and core principles
- Is VEGF inhibition the mainstay for the management of retinal disease?
- Advanced imaging techniques: Identifying imaging biomarkers in dry AMD and other retinal diseases
EYLEA (aflibercept) 8 mg: Real-world insights from US and UK clinicians
These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg in clinical practice for licensed indications. Each video includes early experiences and key learnings from real-world cases, designed to aid understanding and help facilitate best practice for EYLEA 8 mg in UK clinical practice.
UK Consultant Ophthalmologists: Sobha Sivaprasad (Moorfields Eye Hospital), Richard Gale (York and Scarborough Teaching Hospitals NHS Foundation Trust) and Serena Salvatore (University Hospitals Bristol and Weston NHS Foundation Trust)
Prescribing information for EYLEA® (aflibercept) can be found here.
Test your knowledge of OCT disease biomarkers in this series of OCT images and associated knowledge-checker questions provided by Professor Richard Gale, consultant ophthalmologist, York Teaching Hospitals NHS Foundation Trust. Can you identify all of the relevant biomarkers?
The knowledge checkers below have been developed for use on desktop computers.
Key developments relating to EYLEA (aflibercept) 8 mg
This poster explores the real-world service costs associated with nAMD clinics in the UK and the relevant impact of clinic strain, treatment durability and drug cost.
Eye on the Horizon podcast series
Episode 6: Beyond the Brain: Navigating Life as Both Neurosurgeon and Patient (NEW!)
Listen to the sixth episode in this podcast series, in which Peter Cackett and guest speaker Henry Marsh (neurosurgeon and author) discuss Henry’s career as a pioneering neurosurgeon and first-hand experience as both doctor and patient. Topics include:
- The qualities that define a great surgeon
- The emotional challenges of working in healthcare and experiencing the healthcare system as a patient
- Key learnings from teaching the next generation of medical professionals
Previous episodes can also be accessed by following the links below.
Join Peter Cackett, a consultant ophthalmologist at NHS Lothian, for this dynamic podcast series. In each episode, Peter meets with a new inspirational guest to discuss their noteworthy career, explore the challenges of today and gain their perspective on topics of the future.
Challenging cases in medical retina
These case study posters feature challenging scenarios across multiple indications in medical retina, provided by a range of clinicians from across the UK. Each poster includes key information from one or two short case studies and invites you to reflect on the steps that you would follow to manage the same cases.
A UK perspective
Richard Gale, Consultant Ophthalmologist, York and Scarborough Teaching Hospitals NHS Foundation Trust
Resources exploring developments and key principles central to medical retina
5-year real-world evidence from Moorfields Eye Hospital.
Marko Lukic, consultant ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
Talking head video series with Dr SriniVas Sadda: Advances in imaging technologies
Imaging expert Dr SriniVas Sadda, Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute and Professor of Ophthalmology at UCLA, USA, explores advances in imaging in medical retina in this talking head video series. In each 10-minute video, Dr Sadda provides a detailed overview of a different imaging technology, including its advantages and disadvantages, as well as its practicalities in clinical practice.
Learn about the basic principles and potential applications of FLIO in medical retina.
Dr SriniVas Sadda, Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute and Professor of Ophthalmology at UCLA, USA
Prescribing information for EYLEA® (aflibercept) can be found here.
Shifting the curve: HCP insights
Abbreviations
AMD, age-related macular degeneration. CBE, Commander of the British Empire. DMO, diabetic macular oedema. FLIO, Fluorescence Lifetime Imaging Ophthalmoscopy. GA, geographic atrophy. GB, Great Britain. HCP, healthcare professional. MDT, multidisciplinary team. nAMD, neovascular age-related macular degeneration. NHS, National Health Service. NI, Northern Ireland. OCT, optical coherence tomography. OCT-A, optical coherence tomography angiography. Q16, every 16 weeks. QR, quick response. RVO, retinal vein occlusion. SEL DESP, South East London Diabetic Eye Screening Programme. T&E, treat-and-extend. UCLA, University of California, Los Angeles. VEGF, vascular endothelial growth factor.
Footnotes
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).[1] For full details please refer to Summary of Product Characteristics.
*After 3 initial doses, the EYLEA 2 mg treatment interval is extended to 2 months. The treatment interval can then be further extended up to 16 weeks, using proactive T&E dosing.[2]
Prescribing information for EYLEA® (aflibercept) can be found here.
PP-EYL-GB-2555 | November 2024